The Valley Desk

NCT04090229 · Interventional trial

A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

Overall registry status Completed

Phase 1

Conditions Atopic Dermatitis

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov